RENATA DE OLIVEIRA COSTA
Projetos de Pesquisa
Unidades Organizacionais
LIM/31 - Laboratório de Genética e Hematologia Molecular, Hospital das Clínicas, Faculdade de Medicina
6 resultados
Resultados de Busca
Agora exibindo 1 - 6 de 6
conferenceObject Clinical Prognostic Models in Diffuse Large B-Cell Lymphoma Patients Are Still Essential in the Rituximab Era(2014) LAGE, Luis Alberto de Padua Covas; COSTA, Renata Oliveira; HALLACK NETO, Abrahao Elias; SIQUEIRA, Sheila; SANTUCCI, Rodrigo; PAULA, Henrique Moura de; PEREIRA, JulianabookPart Linfomas(2013) PEREIRA, Juliana; COSTA, Renata Oliveira; HALLACK NETO, Abrahão EliasconferenceObject Nodal Peripheral T-Cell Lymphoma - a Clinical and Epidemiological Analysis at Medicine School of Sao Paulo University(2014) LAGE, Luis Alberto de Padua Covas; GONCALVES, Marianne Castro; SANTUCCI, Rodrigo; COSTA, Renata Oliveira; LEVY, Debora; ZERBINI, Maria Claudia; PEREIRA, JulianaconferenceObject Adult T-Cell Leukemia/Lymphoma: A Clinical and Epidemiological Analysis at the Medicine School of Sao Paulo University(2015) CORDEIRO, Ana Costa; LAGE, Luis Alberto de Padua Covas; COSTA, Renata Oliveira; LEVY, Debora; PEREIRA, Juliana- T-cell large granular lymphocytic leukemia: treatment experience with fludarabine(2012) COSTA, Renata Oliveira; BELLESSO, Marcelo; CHAMONE, Dalton Alencar Fischer; RUIZ, Milton Artur; HALLACK NETO, Abrahao Elias; ALDRED, Vera Lucia; PEREIRA, JulianaOBJECTIVES: The aim of this retrospective study was to investigate the results of T-cell large granular lymphocytic leukemia treatment with fludarabine by assessing the complete hematologic response, the complete molecular response, progression-free survival, and overall survival. METHODS: We evaluated the records of six patients with T-cell large granular lymphocytic leukemia who were treated with fludarabine as a first-, second-, or third-line therapy, at a dose of 40 mg/m(2), for three to five days per month and 6 to 8 cycles. RESULTS: Of the six patients investigated with T-cell large granular lymphocytic leukemia who were treated with fludarabine, five (83.3%) were female, and their median age was 36.5 years (range 18 to 73). The median lymphocyte level was 3.4x10(9)/L (0.5 to 8.9). All patients exhibited a monoclonal T-cell receptor gamma gene rearrangement at diagnosis. Two (33.3%) patients received fludarabine as first-line treatment, two (33.3%) for refractory disease, one (16.6%) for relapsed disease after the suspension of methotrexate treatment due to liver toxicity, and one (16.6%) due to dyspesia. A complete hematologic response was achieved in all cases, and a complete molecular response was achieved in five out six cases (83.3%). During a mean follow-up period of 12 months, both the progression-free survival and overall survival rates were 100%. CONCLUSION: T-cell large granular lymphocytic leukemia demonstrated a high rate of complete hematologic and molecular response to fludarabine, with excellent compliance and tolerability rates. To confirm our results in this rare disease, we believe that fludarabine should be tested in clinical trials as a first-line treatment for T-cell large granular lymphocytic leukemia.
conferenceObject 18 F-FDG PET Interim and Determination of Cellular Origin By Immunohistochemistry Identify a Group of Very Good Prognosis in Patients with Diffuse Large B-Cell Lymphoma in the Rituximab Era(2014) LAGE, Luis Alberto de Padua Covas; COSTA, Renata Oliveira; HALLACK NETO, Abrahaeo Elias; SIQUEIRA, Sheila; SANTUCCI, Rodrigo; PAULA, Henrique Moura de; PEREIRA, Juliana